Promoting access of hydroxyurea to sickle cell disease individuals: Time to make it an essential medicine

Hydroxyurea (HU) alone has the potential to prevent one out of every three deaths due to sickle cell disease (SCD) and almost all forms of disabilities caused by SCD. However, in Tanzania, only one out of every six registered SCD patients in the SPARCO-Tanzania Sickle Cell Cohort use HU. We conducte...

Descripción completa

Detalles Bibliográficos
Autores principales: Kilonzi, Manase, Mlyuka, Hamu, Jonathan, Agnes, Tutuba, Hilda, Chirande, Lulu, Rugajo, Paschal, Kida, Irene, Balandya, Emmanuel, Makani, Julie, Sirili, Nathanael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2022
Materias:
Policy Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457563/
https://www.ncbi.nlm.nih.gov/pubmed/37638133
http://dx.doi.org/10.12688/f1000research.111300.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457563/
https://www.ncbi.nlm.nih.gov/pubmed/37638133
http://dx.doi.org/10.12688/f1000research.111300.1

Ejemplares similares